

**SASTASUNDAR VENTURES LIMITED**

Azimganj House, 2nd Floor,  
7 Abanindra Nath Thakur Sarani (Formerly Camac Street),  
Kolkata 700017, India. Tel: +91 33 2282 9330; Fax: +91 33 2282 9335  
Email: info@sastasundar.com; Website: www.sastasundarventures.com  
CIN: L65993WB1989PLC047002

Date: 12-08-2025

To  
The General Manager  
Department of Corporate Services  
BSE Limited  
Phiroze Jeejeebhoy Tower,  
Dalal Street, Mumbai - 400 001

Manager - Listing  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, Bandra Kurla Complex,  
Mumbai - 400 051

Ref: Script Code: 533259 and Symbol: SASTASUNDR

Sub: Outcome of Board meeting held today, the 12<sup>th</sup> August, 2025

Dear Sir/ Madam,

Please find below the outcome of the Meeting of the Board of Directors of the Company held today, the 12th August, 2025:

1. Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, this is to inform you that the Board of Directors of the Company has approved and taken on record the Unaudited Financial Results (both Standalone and Consolidated) for the quarter ended 30th June, 2025 and Limited Review Report of the Statutory Auditor on the financial results. The said results have been reviewed by the Audit Committee of the Board.

A copy of the Unaudited Financial Results (both Standalone and Consolidated) of the Company for the quarter ended 30th June, 2025 along with the Limited Review Report of the Statutory Auditor thereon is enclosed herewith.

The Meeting of the Board of Directors of the Company commenced at 3:30 PM and concluded at 4:30 PM.

Kindly take note of the above and acknowledge the receipt.

Thanking you,

For Sastasundar Ventures Limited

Pratap Singh  
Company Secretary and Compliance Officer  
Mem. No.: ACS-24081

Encl: As above

# JKVS & CO

Chartered Accountants

7/1B Hazra Road, Kolkata-700026 (India)

Phone: +91 33 2476 5068 • E-mail: [kolkata@jkvs.in](mailto:kolkata@jkvs.in)

**Independent Auditor's Review Report on the Unaudited Financial Results of M/s. Sastasundar Ventures Limited for the Quarter Ended June 30, 2025 Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

To,  
The Board of Directors  
Sastasundar Ventures Limited

1. We have reviewed the accompanying statement of unaudited financial results of **M/s. Sastasundar Ventures Limited** (the 'Company') for the quarter ended June 30, 2025 together with the notes thereon (herein after referred to as the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Listing Regulation').
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, in their meeting held on August 12, 2025, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India (I.C.A.I). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') as prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulation, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. The figures for the quarter ended March 31, 2025 as reported in the Statement, being the balancing figure between the audited figures in respect of the full financial year ended on March 31, 2025 and the published unaudited year to date figures up to the third quarter ended December 31, 2024. Also, the figures up to end of the third quarter had only been reviewed by us, as required under the Listing regulations and not subjected to audit.



FOR JKVS & CO  
Chartered Accountants  
Firm Registration No.318086E

*Utsav Saraf*

Utsav Saraf  
Partner  
Membership No. 306932

UDIN:25306932BMNWQN3635

Place: Kolkata

Date: August 12, 2025

[www.jkvs.in](http://www.jkvs.in)

Also at New Delhi & Mumbai

# Sastasundar Ventures Limited

CIN - L65993WB1989PLC047002

Azinganj House, 2nd Floor, 7 Abanindra Nath Thakur Sarani (formerly Camac Street), Kolkata - 700 017

Phone - 033-2282 9331, Fax - 033-2282 9335

Email: investors@sastasundar.com • Website: www.sastasundarventures.com

## STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025

(Rs. in Lakhs except for EPS)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30.06.2025 (Unaudited)	31.03.2025 (Audited) (Refer Note 3)	30.06.2024 (Unaudited)	31.03.2025 (Audited)
(i)	Revenue from Operations				
	Interest Income	9.67	10.31	8.19	40.40
I	<b>Total Revenue from Operations</b>	<b>9.67</b>	<b>10.31</b>	<b>8.19</b>	<b>40.40</b>
II	Other Income	25.68	19.73	22.04	79.91
III	<b>Total income (I+II)</b>	<b>35.35</b>	<b>30.04</b>	<b>30.23</b>	<b>120.31</b>
	<b>Expenses</b>				
(i)	Finance costs	5.52	0.31	0.29	1.19
(ii)	Employee benefit expense	7.44	9.03	12.42	46.69
(iii)	Depreciation and amortisation expense	2.40	2.49	2.43	9.81
(iv)	Other Expenses	30.94	25.04	37.24	133.99
IV	<b>Total Expenses</b>	<b>46.30</b>	<b>36.87</b>	<b>52.38</b>	<b>191.68</b>
V	<b>Profit/(Loss) before tax (III + IV )</b>	<b>(10.95)</b>	<b>(6.83)</b>	<b>(22.15)</b>	<b>(71.37)</b>
VI	<b>Tax expense</b>				
(i)	Current tax	-	-	-	-
(ii)	Deferred tax expense / (credit)	-	-	-	-
	<b>Total</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
VII	<b>Net Profit/(Loss) after tax (V-VI)</b>	<b>(10.95)</b>	<b>(6.83)</b>	<b>(22.15)</b>	<b>(71.37)</b>
VIII	<b>Other Comprehensive Income</b>				
(i)	(a) Items that will be not reclassified subsequently to profit or loss (net of tax)				
	Remeasurement gain/loss on defined benefit plans (net of tax)	(0.52)	(3.17)	0.52	(1.61)
	(b) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
	Sub Total (i)	(0.52)	(3.17)	0.52	(1.61)
(ii)	(a) Items that will be reclassified subsequently to profit or loss (net of tax)	-	-	-	-
	(b) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	Sub Total ( ii )	-	-	-	-
	<b>Other Comprehensive Income/ (Loss) ( i + ii )</b>	<b>(0.52)</b>	<b>(3.17)</b>	<b>0.52</b>	<b>(1.61)</b>
IX	<b>Total Comprehensive Income/ (Loss) ( VII + VIII )</b>	<b>(11.47)</b>	<b>(10.00)</b>	<b>(21.63)</b>	<b>(72.98)</b>
X	Paid-up equity share capital (face value of Rs. 10/- each)	3,181.05	3,181.05	3,181.05	3,181.05
XI	Other Equity (excluding Revaluation Reserves)				23,999.48
XII	<b>Basic and Diluted earning/ (loss) per share (face value of Rs. 10/- each)</b>	<b>(0.03)*</b>	<b>(0.02)*</b>	<b>(0.07)*</b>	<b>(0.22)</b>

\* Not annualised



## **Sastasundar Ventures Limited**

CIN - L65993WB1989PLC047002

Azimganj House, 2nd Floor, 7 Abanindra Nath Thakur Sarani (formerly Camac Street), Kolkata - 700 017

Phone - 033-2282 9331, Fax - 033-2282 9335

Email: investors@sastasundar.com • Website: www.sastasundarventures.com

### **Notes:**

- 1 The above Unaudited Financial Results for the quarter ended June 30, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at this meeting held on August 12, 2025. The Limited review for the quarter ended June 30, 2025 has been carried out by the Statutory Auditors, as required under Regulation 33 of SEBI (LODR) Regulation, 2015.
- 2 The Company being a Core Investment Company has only one reportable business segment and operates in only one geographical segment i.e. "within India".
- 3 The figure for the quarter ended March 31, 2025 are the balancing figure between audited figure in respect of the full financial year and the unaudited published period to date reviewed figures upto the end of the third quarter December 31, 2024 which were subjected to a limited review.
- 4 Previous Year/ Period figures have been re-grouped / re-classified wherever necessary.

For Sastasundar Ventures Limited



A handwritten signature in blue ink, appearing to read "Banwari Lal Mittal".

Banwari Lal Mittal  
Chairman cum Managing Director  
DIN: 00365809

Date : August 12, 2025  
Place : Kolkata



**Independent Auditor's Review Report on the Unaudited Consolidated Financial Results of M/s. Sastasundar Ventures Limited for the quarter ended June 30, 2025 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

Review Report to  
The Board of Directors  
Sastasundar Ventures Limited

1. We have reviewed the accompanying unaudited consolidated financial results of M/s. Sastasundar Ventures Limited ("the Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") and its share of the net profit after tax and total comprehensive profit for the quarter ended June 30, 2025 which are included in the accompanying 'Consolidated Financial Results' of profit and loss for the quarter ended June 30, 2025 ("the Statement"). The statement is being submitted by the Holding Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulation").
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors in their meeting held on August 12, 2025, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133, of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity," issued by Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the financial results of the following entities:

Sl. No.	Name of the Company	Relationship with the Holding Company
1	Sastasundar Ventures Limited	Holding Company
2	Microsec Resources Private Limited	Wholly owned Subsidiary
3	Innogrow Technologies Limited	Wholly owned Subsidiary
4	Bharatiya Sanskriti Village Private Limited	Wholly owned Subsidiary
5	Happymate Foods Limited (till 30 <sup>th</sup> May'2025)	Step-down Subsidiary
6	Genu Path Labs Limited	Step-down Subsidiary
7	Myjoy Technologies Private Limited	Step-down Subsidiary
8	Alokik Advisory Services LLP	Step-down Subsidiary
9	Dreamscape Advisors LLP	Step-down Subsidiary
10	Ruchika Advisory Services LLP	Step-down Subsidiary

Sl. No.	Name of the Company	Relationship with the Holding Company
12	Microsec Invictus Advisors LLP	Step-down Subsidiary
13	Microsec Wealth Management Limited	Step-down Subsidiary
14	Sastasundar Healthbuddy Limited	Subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the management reviewed interim financial results of subsidiaries referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the applicable Indian Accounting Standards as prescribed under Section 133 of the Companies Act, 2013, as amended read with relevant rules issued there under and other recognized accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

#### Other Matters:

6. a. The Statement includes the interim financial statement of Nine ("9") step-down subsidiaries which have not been reviewed by their auditor, whose interim financial statement reflect total revenue of Rs. 156.08 lakhs, total net loss of Rs. 134.79 lakhs and total comprehensive loss of Rs. 129.06 lakhs for the quarter ended June 30, 2025 and as considered in the Statement. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.
- b. We did not review the interim financial statement of three ("3") subsidiaries included in the statement, whose interim financial statement reflect total revenue of Rs. 2,023.74 lakhs, total net profit of Rs. 1,680.70 lakhs and total comprehensive income of Rs. 1,680.24 lakhs for the quarter ended June 30, 2025 and as considered in the Statement. This financial result has been reviewed by other auditor, whose results has been furnished to us by the management. Our conclusion in so far as it relates to the amount and disclosures included in respect of this subsidiary and associate is based solely on the report of the other auditor and procedure performed by us as stated in paragraph 3 above. Our conclusion on the Statement is not modified in respect of the above matters.
7. The figures for the quarter ended March 31, 2025 as reported in the Statement, being the balancing figure between the audited figures in respect of the full financial year ended on March 31, 2025 and the published unaudited year to date figures up to the third quarter ended December 31, 2024. Also, the figures up to end of the third quarter had only been reviewed by us, as required under the Listing regulations and not subjected to audit.
- Our conclusion on the Statement is not modified in respect of the above matter.



For J K V S & CO  
Chartered Accountants  
Firm Registration No. 318086E

Utsav Saraf

Utsav Saraf  
Partner

Membership No. 306932  
UDIN:25306932BMNWQ01538

Place: Kolkata  
Dated: August 12, 2025

# Sastasundar Ventures Limited

CIN -L65993WB1989PLC047002

Azimganj House, 2nd Floor, 7 Abanindra Nath Thakur Sarani (formerly Camac Street), Kolkata - 700 017

Phone - 033-2282 9331, Fax - 033-2282 9335

Email: investors@sastasundar.com • Website: www.sastasundarventures.com

## STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025

(Rs. in Lakhs except for EPS)

Sr. No.	Particulars	Quarter Ended		Year Ended	
		30.06.2025 (Unaudited)	31.03.2025 (Audited) (Refer Note 7)	30.06.2024 (Unaudited)	31.03.2025 (Audited)
	<b>Revenue from operations</b>				
(i)	Interest Income	20.16	18.59	18.75	75.71
(ii)	Dividend Income	-	-	2.64	30.38
(iii)	Net gain on fair value changes	1,968.75	371.13	710.04	2,142.40
(iv)	Sale of products	27,783.42	28,124.32	26,199.35	108,498.21
(v)	Sale of services	70.49	68.87	87.06	313.08
(vi)	Other financial income	-	1.14	11.45	35.68
<b>I</b>	<b>Total Revenue from Operations</b>	<b>29,842.82</b>	<b>28,584.05</b>	<b>27,029.29</b>	<b>111,095.46</b>
<b>II</b>	<b>Other Income</b>	<b>2,538.18</b>	<b>2,162.74</b>	<b>2,774.99</b>	<b>5,984.05</b>
<b>III</b>	<b>Total Income (I+II)</b>	<b>32,381.00</b>	<b>30,746.79</b>	<b>29,804.28</b>	<b>117,079.51</b>
	<b>Expenses</b>				
(i)	Finance costs	8.60	1.30	9.67	21.72
(ii)	Cost of materials consumed	25.19	30.95	61.82	174.10
(iii)	Purchases of stock-in-trade	26,021.54	26,865.39	24,476.74	101,577.48
(iv)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(287.12)	(366.79)	(266.36)	(10.57)
(v)	Employee benefit expense	1,734.09	1,631.27	1,061.91	4,979.32
(vi)	Depreciation and amortisation expense	116.83	133.68	160.80	582.88
(vii)	Other Expenses	1,743.21	2,942.45	1,935.37	9,977.77
<b>IV</b>	<b>Total Expenses</b>	<b>29,362.34</b>	<b>31,238.25</b>	<b>27,439.95</b>	<b>117,302.70</b>
<b>V</b>	<b>Profit/(Loss) before exceptional items, tax and share of profit/(loss) of associate (III - IV)</b>	<b>3,018.66</b>	<b>(491.46)</b>	<b>2,364.33</b>	<b>(223.19)</b>
<b>VI</b>	<b>Exceptional Items [Refer Note 3]</b>	<b>-</b>	<b>28.00</b>	<b>100.00</b>	<b>(19,062.91)</b>
<b>VII</b>	<b>Profit/(Loss) before tax and share of profit/(loss) of associate (V + VI)</b>	<b>3,018.66</b>	<b>(463.46)</b>	<b>2,464.33</b>	<b>(19,286.10)</b>
<b>VIII</b>	<b>Tax expense</b>				
(i)	Current tax	31.15	(611.82)	91.21	940.65
(ii)	Deferred tax expense / (credit)	328.30	(1,081.30)	(2,623.81)	(7,425.31)
(iii)	Short/ (excess) Provision for Tax relating to earlier year	-	(527.55)	-	(527.54)
	<b>Total</b>	<b>359.45</b>	<b>(2,220.67)</b>	<b>(2,532.60)</b>	<b>(7,012.20)</b>
<b>IX</b>	<b>Net Profit/(Loss) after tax and before share of profit/(loss) of associate (VII - VIII)</b>	<b>2,659.21</b>	<b>1,757.21</b>	<b>4,996.93</b>	<b>(12,273.90)</b>
<b>X</b>	<b>Share of Profit/(Loss) of Associate accounted for using equity method (Net of Tax)</b>	<b>-</b>	<b>-</b>	<b>(900.35)</b>	<b>(1,080.40)</b>
<b>XI</b>	<b>Net Profit/(Loss) after tax and share of profit/(loss) of associate (IX + X)</b>	<b>2,659.21</b>	<b>1,757.21</b>	<b>4,096.58</b>	<b>(13,354.30)</b>
<b>XII</b>	<b>Other Comprehensive Income/ (Loss)</b>				
(i)	(a) Items that will be not reclassified subsequently to profit or loss	24.12	(95.00)	25.98	(67.18)
	(b) Income tax relating to items that will not be reclassified to profit or loss	0.18	22.96	0.09	22.38
	Sub Total ( i )	24.30	(72.04)	26.07	(44.80)
(ii)	(a) Items that will be reclassified subsequently to profit or loss	-	-	-	-
	(b) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	Sub Total ( ii )	-	-	-	-
	<b>Other Comprehensive Income/ (Loss) ( i + ii )</b>	<b>24.30</b>	<b>(72.04)</b>	<b>26.07</b>	<b>(44.80)</b>
<b>XIII</b>	<b>Total Comprehensive Income/ (Loss) (XI + XII)</b>	<b>2,683.51</b>	<b>1,685.17</b>	<b>4,122.65</b>	<b>(13,399.10)</b>
<b>XIV</b>	<b>Profit/ (Loss) for the year attributable to</b>				
(i)	Owner of the company	2,391.17	1,367.20	3,115.12	(9,116.71)
(ii)	Non-Controlling Interests	268.04	390.01	981.46	(4,237.59)
<b>XV</b>	<b>Other Comprehensive Income/ (Loss) for the period attributable to</b>				
(i)	Owners of the company	17.19	(53.11)	19.03	(32.81)
(ii)	Non-Controlling Interests	7.11	(18.93)	7.04	(11.99)
<b>XVI</b>	<b>Total Comprehensive Income/ (Loss) for the period attributable to</b>				
(i)	Owners of the company	2,408.36	1,314.09	3,134.15	(9,149.52)
(ii)	Non-Controlling Interests	275.15	371.08	988.50	(4,249.58)
<b>XVII</b>	<b>Paid-up equity share capital (face value of Rs. 10/- each)</b>	<b>3,181.05</b>	<b>3,181.05</b>	<b>3,181.05</b>	<b>3,181.05</b>
<b>XVIII</b>	<b>Other Equity (excluding Revaluation Reserves)</b>				<b>63,806.05</b>
<b>XIX</b>	<b>Earnings per Share</b>				
	Basic	7.52*	4.30*	9.79*	(28.66)
	Diluted	7.52*	4.30*	9.79*	(28.66)

\* Not annualised



# Sastasundar Ventures Limited

CIN -L65993WB1989PLC047002

Azimganj House, 2nd Floor, 7 Abanindra Nath Thakur Sarani (formerly Camac Street), Kolkata - 700 017

Phone - 033-2282 9331, Fax - 033-2282 9335

Email: investors@sastasundar.com • Website: www.sastasundarventures.com

## Segment wise Revenue, Results, Assets and Liabilities for the Quarter Ended June 30, 2025

(Rs. in Lakhs)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30.06.2025 (Unaudited)	31.03.2025 (Audited) (Refer Note 7)	30.06.2024 (Unaudited)	31.03.2025 (Audited)
<b>1</b>	<b>Segment Revenue</b>				
(a)	Financial Services	1,988.92	390.93	742.88	2,284.16
(b)	Healthcare Network	27,853.90	28,193.12	26,286.41	108,811.30
	<b>Total</b>	<b>29,842.82</b>	<b>28,584.05</b>	<b>27,029.29</b>	<b>111,095.46</b>
	Less : Inter Segment Revenue	-	-	-	-
	<b>Income from Operations</b>	<b>29,842.82</b>	<b>28,584.05</b>	<b>27,029.29</b>	<b>111,095.46</b>
<b>2</b>	<b>Segment Results</b>				
	<b>Profit / (Loss) before Finance Costs and Tax</b>				
(a)	Financial Services	1,949.59	357.72	681.02	2,053.05
(b)	Healthcare Network	(1,308.77)	(1,894.34)	(875.60)	(25,931.37)
	<b>Total</b>	<b>640.82</b>	<b>(1,536.62)</b>	<b>(194.58)</b>	<b>(23,878.32)</b>
	Less:				
	Finance Costs	8.60	1.30	9.67	21.72
	Other unallocable expenditure net of unallocable income	(2,386.44)	(1,074.46)	(2,668.58)	(4,613.94)
	<b>Profit / (Loss) before tax</b>	<b>3,018.66</b>	<b>(463.46)</b>	<b>2,464.33</b>	<b>(19,286.10)</b>
<b>3</b>	<b>Segment Assets</b>				
(a)	Financial Services	12,179.59	10,146.80	9,142.79	10,146.80
(b)	Healthcare Network	81,224.00	82,490.70	104,897.97	82,490.70
(c)	Unallocated	4,800.80	4,799.64	4,044.13	4,799.64
	<b>Total</b>	<b>98,204.39</b>	<b>97,437.14</b>	<b>118,084.89</b>	<b>97,437.14</b>
<b>4</b>	<b>Segment Liabilities</b>				
(a)	Financial Services	755.65	451.81	384.28	451.81
(b)	Healthcare Network	8,184.39	10,398.70	13,193.07	10,398.70
(c)	Unallocated	127.35	133.14	431.47	133.14
	<b>Total</b>	<b>9,067.39</b>	<b>10,983.65</b>	<b>14,008.82</b>	<b>10,983.65</b>



## Sastasundar Ventures Limited

CIN -L65993WB1989PLC047002

Azimganj House, 2nd Floor, 7 Abanindra Nath Thakur Sarani (formerly Camac Street), Kolkata - 700 017

Phone - 033-2282 9331, Fax - 033-2282 9335

Email: investors@sastasundar.com • Website: www.sastasundarventures.com

### Notes:

- 1 The above Unaudited Consolidated Financial Results for the quarter ended June 30, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on August 12, 2025. The Limited Review for the quarter ended June 30, 2025 has been carried out by the Statutory Auditors, as required under Regulation 33 of SEBI (LODR) Regulation, 2015.
- 2 The Group has identified the following segments :
  - (a) Financial Services - consists mainly of financing of loans and investment in shares and securities, financial consultancy, professional fees, wealth management, financial planning, distribution and related services.
  - (b) Healthcare Network - includes activities for pathology, food processing and marketing of healthcare and OTC products through e-commerce portal and diagnostic services which consist of pathological / radiological investigations.
- 3 **Exceptional items represent the gain on following transaction/ event:**
  - (a) During the Financial Year 2022-23, subsidiaries of the Company had expensed Rs. 796.45 Lakhs under the heading "Exceptional Item". During the previous year, Sastasundar Healthbuddy Limited, subsidiary of the Company has now recovered Rs. 128.00 Lakhs against the aforesaid amount which has been booked as income in the consolidated financial result for the year ended March 31, 2025 under the heading "exceptional item" including Rs. 28.00 Lakhs of previous quarter March 2025.
  - (b) During the previous year, the subsidiary of the company, Sastasundar Healthbuddy Limited, has liquidated its investment held in the form of 0.01% Non-Cumulative Compulsory Convertible Preference share and Equity shares in Flipkart Health Limited on 29th October 2024 as per Share Purchase Agreement dated 28th October 2024 and received a consideration of Rs. 9,717.29 Lakhs in aggregate.  
This has resultant loss of Rs. 19,118.54 Lakhs has been booked as exceptional items in the consolidated financial result for the year ended March 31, 2025.
  - (c) During the previous year, the management of one of the step down subsidiary, Genu Path Labs Limited, has evaluated its business operation and the management is of the opinion that the Property, Plant & Equipment as held by it needs to be impaired. Accordingly the company has accounted for an impairment loss of Rs 72.37 Lakhs and disclosed the same as Exceptional item in the consolidated financial result for the year ended March 31, 2025.
- 4 (a) During the year ended 31st March 2025, the subsidiary of the Company, Sastasundar Healthbuddy Limited, has entered into an agreement to dispose of its subsidiary, Happy Mate Foods Limited, and accordingly classified the investment in the said entity as Asset Held for Sale in accordance with Ind AS 105 – Non-current Assets Held for Sale and Discontinued Operations.  
  
On May 30, 2025, the sale of Happy Mate Foods Limited was completed, and the entity ceased to be a subsidiary of Sastasundar Healthbuddy Limited with effect from that date.
- 5 During the previous year, the subsidiary of the company, Sastasundar Healthbuddy Limited, has liquidated its investment in Associate Company i.e. Flipkart Health Limited on October 29, 2024. Share of Profit/ (Loss) from an associate company has been consolidated till October 29, 2024.
- 6 Genu Path Labs Limited, step- down subsidiary of the company, commenced its operations in the diagnostics and healthcare services segment in 2018 with a vision to establish itself as a trusted brand. Since inception, the company has undertaken several initiatives to develop its service network and physical presence. However, these efforts have not yielded the expected outcomes, resulting in operational losses. Additionally, Sastasundar Healthbuddy Limited, parent company of the Genu Path Labs Limited has assured its continued financial support to implement the revised strategies aimed at reviving and strengthening the business.
- 7 The figure for the quarter ended March 31, 2025 are the balancing figure between audited figure in respect of the full financial year and the unaudited published period to date reviewed figures upto the end of the third quarter December 31, 2024 which were subjected to a limited review.
- 8 Previous Period/ Year figures have been re-grouped / re-classified wherever necessary.

Date : August 12, 2025  
Place : Kolkata



For Sastasundar Ventures Limited

Banwari Lal Mittal  
Chairman cum Managing Director  
DIN : 00365809

